Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium
Sonu Bhaskar(New South Wales Department of Health), Susana Mederer Hengstl(Complejo Hospitalario de Pontevedra), Nirmal Surya(Surya Hospitals), Simon Israeli‐Korn(Tel Aviv University), Sandra Santarrufina Martínez(Hospital da Restauração), Vijay Kumar Chattu(University of Washington), Koravangattu Valsraj(South London and Maudsley NHS Foundation Trust), Bindu Menon(Apollo Hospitals), Pravin Thomas(University Hospitals Birmingham NHS Foundation Trust), Mandana Toosi(Eastern Illinois University), Jasvinder Chawla(Loyola University Medical Center), Nithya Hariya Mohan, Sailaja Golla, Rajeev Kumar(Australian National University), Daniel Ray(Queen Elizabeth Hospital Birmingham), John Codrington(Academic Hospital Paramaribo), Harvey Yang(Academic Hospital Paramaribo), Sian Bradley(UNSW Sydney), Eva María Jiménez González, Abderrahmane Chahidi(Université Sorbonne Nouvelle), Mihriban Heval Özgen(Leiden University), Paolo Prandi(University of Verona)
Cited by 91
Related Papers
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019
|The Lancet Public Health|2022|5.4k
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
|The Lancet Rheumatology|2023|1.7k
Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021
|The Lancet Haematology|2023|674
Cytokine Storm in COVID-19—Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper
|Frontiers in Immunology|2020|519
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
|Particle and Fibre Toxicology|2010|491